Phase II trial of combination weekly bortezomib (Velcade) and docetaxel (Taxotere) in patients with recurrent and/ or metastatic head and neck squamous cell carcinoma (HNSCC).
Phase of Trial: Phase II
Latest Information Update: 02 Nov 2011
At a glance
- Drugs Bortezomib (Primary) ; Docetaxel
- Indications Head and neck cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Takeda Oncology
- 01 Apr 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 25 Nov 2010 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
- 16 Feb 2007 New trial record.